The resultant high frequency of patients with cardiovascular disease being prescribed phosphodiesterase‐5 (PDE5) inhibitors for ED has driven efforts to identify the effects of PDE5 inhibitors on the cardiovascular system and clinical trials have studied the role of PDE5 inhibitors in cardiac disease [4, 5, 6, 7]. Here, PDE5A is linked to heart disorder.